Chronic myelogenous leukemia (CML) (chronic myeloid leukemia or chronic granulocytic leukemia)
The VA rates Chronic myelogenous leukemia (CML) (chronic myeloid leukemia or chronic granulocytic leukemia) under Diagnostic Code 7719 across 3 severity levels, from 30% to 100%. At 100%, veterans receive $3939/month or more in compensation.
Rating schedule — DC 7719 at a glance
- Minimum rating
- 30%
- Maximum rating
- 100%
- Rating tiers
- 3
- CFR section
- § 4.117
- Body system
- Hematologic & Lymphatic System
- Secondary conditions
- 0
Lowest schedular rating available
Full schedular disability
30%, 60%, 100%
Part 4 rating schedule
None mapped
What are the VA rating criteria for Chronic myelogenous leukemia (CML) (chronic myeloid leukemia or chronic granulocytic leukemia)?
| Rating | Criteria |
|---|---|
| 30% | In apparent remission on continuous molecularly targeted therapy with tyrosine kinase inhibitors |
| 60% | Requiring intermittent myelosuppressive therapy, or molecularly targeted therapy with tyrosine kinase inhibitors, or interferon treatment when not in apparent remission |
| 100% | Requiring peripheral blood or bone marrow stem cell transplant, or continuous myelosuppressive or immunosuppressive therapy treatment |
“Requiring intermittent myelosuppressive therapy, or molecularly targeted therapy with tyrosine kinase inhibitors, or interferon treatment when not in apparent remission”
Common Questions About Chronic myelogenous leukemia (CML) (chronic myeloid leukemia or chronic granulocytic leukemia) VA Ratings
What is the VA rating range for Chronic myelogenous leukemia (CML) (chronic myeloid leukemia or chronic granulocytic leukemia)?
The VA rates Chronic myelogenous leukemia (CML) (chronic myeloid leukemia or chronic granulocytic leukemia) under Diagnostic Code 7719 at 30%, 60%, 100%. The minimum 30% rating requires: In apparent remission on continuous molecularly targeted therapy with tyrosine kinase inhibitors. The maximum 100% rating requires: Requiring peripheral blood or bone marrow stem cell transplant, or continuous myelosuppressive or immunosuppressive therapy treatment.
Which 38 CFR diagnostic code does the VA use for Chronic myelogenous leukemia (CML) (chronic myeloid leukemia or chronic granulocytic leukemia)?
The VA rates Chronic myelogenous leukemia (CML) (chronic myeloid leukemia or chronic granulocytic leukemia) under Diagnostic Code (DC) 7719, governed by 38 CFR 38 CFR § 4.117. The diagnostic code establishes the specific rating tiers and severity criteria the VA examiner applies.
What is the difference between a 30% and a 100% rating for Chronic myelogenous leukemia (CML) (chronic myeloid leukemia or chronic granulocytic leukemia)?
A 30% rating requires: In apparent remission on continuous molecularly targeted therapy with tyrosine kinase inhibitors. A 100% rating requires: Requiring peripheral blood or bone marrow stem cell transplant, or continuous myelosuppressive or immunosuppressive therapy treatment. The difference typically reflects the frequency, severity, or functional impact of the condition as documented in medical records and C&P examination findings.
Can Chronic myelogenous leukemia (CML) (chronic myeloid leukemia or chronic granulocytic leukemia) qualify for TDIU?
Yes — a 100% rating for Chronic myelogenous leukemia (CML) (chronic myeloid leukemia or chronic granulocytic leukemia) alone meets the single-disability threshold for TDIU (38 CFR § 4.16). If the condition prevents substantially gainful employment, the veteran is compensated at the 100% rate without a schedular 100% rating.
What evidence supports a higher rating for Chronic myelogenous leukemia (CML) (chronic myeloid leukemia or chronic granulocytic leukemia)?
The key evidence for Chronic myelogenous leukemia (CML) (chronic myeloid leukemia or chronic granulocytic leukemia) is documentation of how the condition affects daily functioning. Treatment records showing worsening symptoms, functional limitations documented by your provider, and buddy statements describing observable impact on daily life all strengthen the claim. A nexus letter from a qualified medical professional linking the current severity to service is essential for contested claims.
What happens at the C&P exam for Chronic myelogenous leukemia (CML) (chronic myeloid leukemia or chronic granulocytic leukemia)?
The C&P examiner uses a Hematologic & Lymphatic System DBQ and evaluates your condition against the DC 7719 rating criteria. The examiner documents symptom frequency, severity, and functional impact. Bring all treatment records and describe your worst days, not your best — the VA rates on the full clinical picture across time, not a snapshot of one good day.
Get a Personalized Rating Analysis
VeteranHQ evaluates your symptoms against the exact 38 CFR criteria, identifies secondary conditions, and shows what evidence you need to support a higher rating.
Discover Your Benefits